Mesoporous hydroxyapatite as a carrier of olanzapine for long-acting antidepression treatment in rats with induced depression

Yan-Jye Shyong, Mao Hsien Wang, Li Wei Kuo, Chang Fu Su, Wei Ting Kuo, Kuo Chi Chang, Feng Huei Lin

研究成果: Article

9 引文 (Scopus)

摘要

An antidepressant carrier, mesoporous hydroxyapatite olanzapine (mesoHAP-OLZ), was designed to maintain 3 weeks of constant medication release. The carrier was intramuscularly (IM) injected, where cellular activity played a role in achieving the goal of constant release. The efficiency of the treatment was evaluated from 3 perspectives in in vivo studies: locomotor activities, biomarkers, and learning and memory ability. MesoHAP-OLZ can increase the locomotor activity in rats with induced depression determined by open field test (OFT) and forced swim test (FST). Serotonin (5-HT), one of the most important biomarker in depression can also be increased by mesoHAP-OLZ, leading to increased hippocampus activity as measured by functional magnetic resonance imaging (fMRI). MesoHAP-OLZ can also improve learning and memory ability in rats with induced depression during Morris water maze (MWM) test. Our findings further show that mesoHAP-OLZ can provide long-term drug release with a single IM injection, helping to solve the problem of non-adherent medication intake that often occurs in antidepressant therapy.

原文English
頁(從 - 到)62-72
頁數11
期刊Journal of Controlled Release
255
DOIs
出版狀態Published - 2017 六月 10

指紋

olanzapine
Durapatite
Aptitude
Locomotion
Depression
Antidepressive Agents
Serotonin
Biomarkers
Learning
Hippocampus
Therapeutics
Magnetic Resonance Imaging
Efficiency
Injections
Water

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science

引用此文

Shyong, Yan-Jye ; Wang, Mao Hsien ; Kuo, Li Wei ; Su, Chang Fu ; Kuo, Wei Ting ; Chang, Kuo Chi ; Lin, Feng Huei. / Mesoporous hydroxyapatite as a carrier of olanzapine for long-acting antidepression treatment in rats with induced depression. 於: Journal of Controlled Release. 2017 ; 卷 255. 頁 62-72.
@article{ae67b6b43f4a4ab88375148ddd05cd19,
title = "Mesoporous hydroxyapatite as a carrier of olanzapine for long-acting antidepression treatment in rats with induced depression",
abstract = "An antidepressant carrier, mesoporous hydroxyapatite olanzapine (mesoHAP-OLZ), was designed to maintain 3 weeks of constant medication release. The carrier was intramuscularly (IM) injected, where cellular activity played a role in achieving the goal of constant release. The efficiency of the treatment was evaluated from 3 perspectives in in vivo studies: locomotor activities, biomarkers, and learning and memory ability. MesoHAP-OLZ can increase the locomotor activity in rats with induced depression determined by open field test (OFT) and forced swim test (FST). Serotonin (5-HT), one of the most important biomarker in depression can also be increased by mesoHAP-OLZ, leading to increased hippocampus activity as measured by functional magnetic resonance imaging (fMRI). MesoHAP-OLZ can also improve learning and memory ability in rats with induced depression during Morris water maze (MWM) test. Our findings further show that mesoHAP-OLZ can provide long-term drug release with a single IM injection, helping to solve the problem of non-adherent medication intake that often occurs in antidepressant therapy.",
author = "Yan-Jye Shyong and Wang, {Mao Hsien} and Kuo, {Li Wei} and Su, {Chang Fu} and Kuo, {Wei Ting} and Chang, {Kuo Chi} and Lin, {Feng Huei}",
year = "2017",
month = "6",
day = "10",
doi = "10.1016/j.jconrel.2017.03.399",
language = "English",
volume = "255",
pages = "62--72",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",

}

Mesoporous hydroxyapatite as a carrier of olanzapine for long-acting antidepression treatment in rats with induced depression. / Shyong, Yan-Jye; Wang, Mao Hsien; Kuo, Li Wei; Su, Chang Fu; Kuo, Wei Ting; Chang, Kuo Chi; Lin, Feng Huei.

於: Journal of Controlled Release, 卷 255, 10.06.2017, p. 62-72.

研究成果: Article

TY - JOUR

T1 - Mesoporous hydroxyapatite as a carrier of olanzapine for long-acting antidepression treatment in rats with induced depression

AU - Shyong, Yan-Jye

AU - Wang, Mao Hsien

AU - Kuo, Li Wei

AU - Su, Chang Fu

AU - Kuo, Wei Ting

AU - Chang, Kuo Chi

AU - Lin, Feng Huei

PY - 2017/6/10

Y1 - 2017/6/10

N2 - An antidepressant carrier, mesoporous hydroxyapatite olanzapine (mesoHAP-OLZ), was designed to maintain 3 weeks of constant medication release. The carrier was intramuscularly (IM) injected, where cellular activity played a role in achieving the goal of constant release. The efficiency of the treatment was evaluated from 3 perspectives in in vivo studies: locomotor activities, biomarkers, and learning and memory ability. MesoHAP-OLZ can increase the locomotor activity in rats with induced depression determined by open field test (OFT) and forced swim test (FST). Serotonin (5-HT), one of the most important biomarker in depression can also be increased by mesoHAP-OLZ, leading to increased hippocampus activity as measured by functional magnetic resonance imaging (fMRI). MesoHAP-OLZ can also improve learning and memory ability in rats with induced depression during Morris water maze (MWM) test. Our findings further show that mesoHAP-OLZ can provide long-term drug release with a single IM injection, helping to solve the problem of non-adherent medication intake that often occurs in antidepressant therapy.

AB - An antidepressant carrier, mesoporous hydroxyapatite olanzapine (mesoHAP-OLZ), was designed to maintain 3 weeks of constant medication release. The carrier was intramuscularly (IM) injected, where cellular activity played a role in achieving the goal of constant release. The efficiency of the treatment was evaluated from 3 perspectives in in vivo studies: locomotor activities, biomarkers, and learning and memory ability. MesoHAP-OLZ can increase the locomotor activity in rats with induced depression determined by open field test (OFT) and forced swim test (FST). Serotonin (5-HT), one of the most important biomarker in depression can also be increased by mesoHAP-OLZ, leading to increased hippocampus activity as measured by functional magnetic resonance imaging (fMRI). MesoHAP-OLZ can also improve learning and memory ability in rats with induced depression during Morris water maze (MWM) test. Our findings further show that mesoHAP-OLZ can provide long-term drug release with a single IM injection, helping to solve the problem of non-adherent medication intake that often occurs in antidepressant therapy.

UR - http://www.scopus.com/inward/record.url?scp=85018271393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018271393&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2017.03.399

DO - 10.1016/j.jconrel.2017.03.399

M3 - Article

C2 - 28392460

AN - SCOPUS:85018271393

VL - 255

SP - 62

EP - 72

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

ER -